MediWound (MDWD) Expected to Announce Earnings on Thursday

MediWound (NASDAQ:MDWD) is anticipated to announce its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $2.0870 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:30 AM ET.

MediWound Trading Down 0.7%

Shares of MediWound stock opened at $17.45 on Thursday. The firm has a market cap of $223.53 million, a PE ratio of -9.18 and a beta of 0.13. The stock has a 50 day moving average of $17.90 and a 200 day moving average of $17.91. MediWound has a 12 month low of $14.14 and a 12 month high of $22.50.

Institutional Trading of MediWound

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Sphera Funds Management LTD. increased its holdings in shares of MediWound by 24.3% during the fourth quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company’s stock valued at $4,252,000 after acquiring an additional 45,077 shares in the last quarter. Kotler Kevin purchased a new position in MediWound in the fourth quarter valued at $6,225,000. Russell Investments Group Ltd. raised its position in shares of MediWound by 45.1% in the fourth quarter. Russell Investments Group Ltd. now owns 3,653 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 1,135 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of MediWound during the 4th quarter worth about $297,000. Finally, Barclays PLC boosted its stake in shares of MediWound by 32.5% during the 4th quarter. Barclays PLC now owns 15,276 shares of the biopharmaceutical company’s stock worth $282,000 after acquiring an additional 3,747 shares in the last quarter. Institutional investors own 46.83% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on MDWD shares. HC Wainwright reiterated a “buy” rating and set a $36.00 target price (up from $31.00) on shares of MediWound in a research report on Friday, November 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research report on Thursday, January 22nd. Zacks Research upgraded shares of MediWound from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Finally, Wall Street Zen upgraded shares of MediWound from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, MediWound has an average rating of “Moderate Buy” and a consensus price target of $33.50.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.